ApicHope(SZ:300723) Zheng Quan Ri Bao Wang·2025-09-16 11:41Core Viewpoint - The company Yipinhong (300723) is collaborating with Arthrosi, a US-based company focused on innovative drug development for metabolic diseases, to develop a new generation of selective uric acid transporter (URAT1) inhibitor, AR882, aimed at treating gout and gout stones [1] Group 1 - The drug AR882 is designed to normalize uric acid salt excretion in urine by inhibiting uric acid reabsorption, thereby lowering serum uric acid (sUA) levels [1] - The global Phase III clinical trial for AR882, excluding mainland China, is expected to complete participant enrollment by August 2025, with ongoing multi-center clinical trials progressing steadily [1] - Drug development is characterized by long cycles, high investment, and significant risks, prompting investors to make cautious decisions [1]